The aim of the current study was to separately investigate the association between SGLT2i,GLP-1 RA, and DPP-4i use with (I) incident hospitalization/death for COVID-19 and (II)mortality in patients with COVID-19 in a nationwide cohort of T2DM patients in Sweden. Here, GLP1R is linked to COVID-19.